BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins™, today reported financial results and business highlights for the third quarter ended September 30, 2014.
“We have made exceptional progress in recent months, including the addition of highly experienced new members of our team who we believe will provide strong leadership for our business and clinical development strategy as well as the expansion of our pipeline,” said Scott Minick, President and CEO. “
Help employers find you! Check out all the jobs and post your resume.
“We have made exceptional progress in recent months, including the addition of highly experienced new members of our team who we believe will provide strong leadership for our business and clinical development strategy as well as the expansion of our pipeline,” said Scott Minick, President and CEO. “
Help employers find you! Check out all the jobs and post your resume.
